The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes
Open accessPublished version of a preprint
The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
In comparison to other human cancer types, malignant melanoma exhibits the greatest amount of heterogeneity. After DNA-based detection of the BRAF V600E mutation in melanoma patients, targeted inhibitor treatment is the current recommendation. This approach, however, does not take the abundance of the therapeutic target, i.e., the B-raf V600E protein, into consideration. As shown by immunohistochemistry, the protein expression profiles of metastatic melanomas clearly reveal the existence of inter- and intra-tumor variability. Nevertheless, the technique is only semi-quantitative. To quantitate the mutant protein there is a fundamental need for more precise techniques that are aimed at defining the currently non-existent link between the levels of the target protein and subsequent drug efficacy. Using cutting-edge mass spectrometry combined with DNA and mRNA sequencing, the mutated B-raf protein within metastatic tumors was quantitated for the first time. B-raf V600E protein analysis revealed a subjacent layer of heterogeneity for mutation-positive metastatic melanomas. These were characterized into two distinct groups with different tumor morphologies, protein profiles and patient clinical outcomes. This study provides evidence that a higher level of expression in the mutated protein is associated with a more aggressive tumor progression. Our study design, comprised of surgical isolation of tumors, histopathological characterization, tissue biobanking, and protein analysis, may enable the eventual delineation of patient responders/non-responders and subsequent therapy for malignant melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, melanoma tumour genomic BRAF driver mutations match corresponding protein sequences97, illustrating that proteomic landscapes add value to genomic data, when considered with patient tumour histopathology and clinical metadata98.”
From A high-stringency blueprint of the human proteome (2020) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Perseus computational platform for comprehensive analysis of (prote)omics data
Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M., & Cox, J. (2016) · Nature Methods · doi:10.1038/nmeth.3901 · Cited by 8,803
Genomic classification of cutaneous melanoma
Akbani, R., Akdemir, K. C., Aksoy, B. A., Albert, M., Ally, A., Amin, S. B., Arachchi, H., Arora, A., Auman, J. T., Ayala, B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.044 · Cited by 3,151
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Balch, C. M., Soong, S.-J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3622 · Cited by 2,388
Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 1×
“Interestingly, a previous study has shown that B-raf V600E-expressing melanocytes display classical hallmarks of senescence, thus suggesting that oncogene-induced senescence represents a genuine protective physiological process [51].”
BackgroundCombined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Research works printed but not linked: 1
- Balch, 2001, Prognostic Factors Analysis of 17, 600 Melanoma Patients: Melanoma Staging System, Society, 19, 3622
Cited by
A high-stringency blueprint of the human proteome
Adhikari, S., Nice, E. C., Deutsch, E. W., Lane, L., Omenn, G. S., Pennington, S. R., Paik, Y.-K., Overall, C. M., Corrales, F. J., Cristea, I. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19045-9 · Cited by 210
Self-citationThe Role of Toll-Like Receptor in Inflammation and Tumor Immunity
Cen, X., Liu, S., & Cheng, K. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00878 · Cited by 188
Melanoma Management: From Epidemiology to Treatment and Latest Advances
Lopes, J., Rodrigues, C. M. P., Gaspar, M. M., & Reis, C. P. (2022) · Cancers · doi:10.3390/cancers14194652 · Cited by 182
BRAF Heterogeneity in Melanoma
Ito, T., Tanaka, Y., Murata, M., Kaku‐Ito, Y., Furue, K., & Furue, M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00818-3 · Cited by 49
Clinical protein science in translational medicine targeting malignant melanoma
Gil, J., Betancourt, L. H., Pla, I., Sanchez, A., Appelqvist, R., Miliotis, T., Kuras, M., Oskolas, H., Kim, Y., Horvath, Z., et al. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09468-6 · Cited by 45
Self-citation
Metadata
- Authors
- Betancourt, L. H., Szasz, A. M., Kuras, M., Rodriguez Murillo, J., Sugihara, Y., Pla, I., Horvath, Z., Pawłowski, K., Rezeli, M., Miharada, K., Gil, J., Eriksson, J., Appelqvist, R., Miliotis, T., Baldetorp, B., Ingvar, C., Olsson, H., Lundgren, L., Horvatovich, P., Welinder, C., Wieslander, E., Kwon, H. J., Malm, J., Nemeth, I. B., Jönsson, G., Fenyö, D., Sanchez, A., & Marko-Varga, G.
- Affiliations
- Lund University (SE)
- Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical, Engineering, Lund University, BMC D13, 221 84 Lund, Sweden
- Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17 177 Stockholm, Sweden
- Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne University Hospital Malmö, 205 02 Malmö, Sweden
- Warsaw University of Life Sciences (PL)
- AstraZeneca (Sweden) (SE)
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, 221 85 Lund, Sweden
- University of Groningen (NL)
- Yonsei University (KR)
- Department of Dermatology and Allergology, University of Szeged, H-6720 Szeged, Hungary
- NYU Langone Health (US)
- ORCID
- Betancourt, Lazaro Hiram
- Szasz, A. Marcell
- Kuras, Magdalena
- Sugihara, Yutaka
- Pla, Indira
- Pawłowski, Krzysztof
- Rezeli, Melinda
- Miharada, Kenichi
- Gil, Jeovanis
- Eriksson, Jonatan
- Appelqvist, Roger
- Miliotis, Tasso
- Ingvar, Christian
- Horvatovich, Peter
- Welinder, Charlotte
- Kwon, Ho Jeong
- Malm, Johan
- Fenyö, David
- Sanchez, Aniel
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-12-09
- Volume
- 11
- Issue
- 12
- Pages
- 1981
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6966659
- OpenAlex
- W2982318968
- Cited by
- 24
- References
- 64
- Citations by year
- 2025: 2 · 2023: 3 · 2022: 2 · 2021: 7 · 2020: 6 · 2019: 3
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- Lund University Publications (Lund University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (KNN121510)
- Berta Kamprad Foundation (01)
- ThermoFisher Scientific (01)
- Liconic Biobanking (01)
- Global (01)
- National Research Foundation of Korea (2015K1A1A2028365 and 2016K2A9A1A03904900)
- Korean Government (2016K2A9A1A03904900)
- Brain Korea 21 (01)
- Republic of Korea (01)
- NIH/NCI International Cancer Proteogenome Consortium (01)
- The Mats Paulsson Trust (01)
- The Stefan Paulsson Trust (01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- metastatic melanoma, BRAF V600E mutation, protein quantification, intratumoral heterogeneity, intertumoral heterogeneity, tumor phenotype, clinical outcomes, targeted therapy, drug response prediction, tumor progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes. https://app.cochat.ai/papers/10.3390/cancers11121981
- The paper
- Betancourt, L. H., Szasz, A. M., Kuras, M., Rodriguez Murillo, J., Sugihara, Y., Pla, I., Horvath, Z., Pawłowski, K., Rezeli, M., Miharada, K., Gil, J., Eriksson, J., Appelqvist, R., Miliotis, T., Baldetorp, B., Ingvar, C., Olsson, H., Lundgren, L., Horvatovich, P., . . . Marko-Varga, G. (2019). The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma—Association with Clinical Outcome and Tumor Phenotypes. Cancers. https://doi.org/10.3390/cancers11121981
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.